Vycor Medical Inc (PK:VYCO)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 951 Broken Sound Parkway, Suite 320 BOCA RATON FL 33487 |
| Tel: | N/A |
| Website: | https://www.vycormedical.com |
| IR: | See website |
| Key People | ||
| Adrian Christopher Liddell Chairman of the Board, Chief Financial Officer | David Marc Cantor President, Director | Peter C. Zachariou Chief Executive Officer, Executive Vice President, Director |
| Business Overview |
| Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company operates through two segments: Vycor Medical and NovaVision. The Company's Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. The Company designs, develops and markets neurological medical devices and therapies. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe. |
| Financial Overview |
| For the nine months ended 30 September 2023, Vycor Medical Inc revenues increased 21% to $1.2M. Net loss applicable to common stockholders excluding extraordinary items decreased 51% to $297K. Revenues reflect Vycor Medical segment increase of 24% to $1.1M. Lower net loss reflects General and administrative decrease of 14% to $882K (expense), Loss on foreign currency exchange decrease from $1K (expense) to $0K. |
| Employees: | 6 as of Dec 31, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $3.65M as of Dec 31, 2023 |
| Annual revenue (TTM): | $1.42M as of Dec 31, 2023 |
| EBITDA (TTM): | $0.07M as of Dec 31, 2023 |
| Net annual income (TTM): | -$0.41M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$0.01M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $0.91M as of Dec 31, 2023 |
| Shares outstanding: | 32,628,835 as of Nov 13, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.